Clinical Trial Update: A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab [Phase 1]

View source ↗

Summary

Phase 1 study evaluating MEDI4736 (durvalumab) in combination with tremelimumab has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cervical Cancer
• Colorectal Cancer
• Ovarian Cancer
• Renal Cell Carcinoma

Drugs mentioned

• MEDI4736 (Durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Ludwig Institute for Cancer Research | Conditions: Breast Cancer, Ovarian Cancer | Phase 1 | Status: COMPLETED | Results posted: 2020-06-22